The health savings account-eligible design may decrease costs and utilization, but it also may decrease use of preventive services.
John M. Brooks, PhD
Advertisement
Articles by John M. Brooks, PhD
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Pharmacists Bridge the Vaccine Trust Gap as COVID-19 Persists
2
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
3
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
4
Preparing Practices for the Next Era of Hepatitis B Care
5